Standard BioTools Inc (NASDAQ: LAB): Is It A Gold Mine Or A Disaster In The Making?

In the last trading session, 1.93 million shares of the Standard BioTools Inc (NASDAQ:LAB) were traded, and its beta was 1.64. Most recently the company’s share price was $2.71, and it changed around $0.02 or 0.74% from the last close, which brings the market valuation of the company to $786.23M. LAB currently trades at a discount to its 52-week high of $3.16, offering almost -16.61% off that amount. The share price’s 52-week low was $1.46, which indicates that the current value has risen by an impressive 46.13% since then. We note from Standard BioTools Inc’s average daily trading volume that its 10-day average is 1.8 million shares, with the 3-month average coming to 1.86 million.

Standard BioTools Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended LAB as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Standard BioTools Inc is expected to report earnings per share of $0 for the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Standard BioTools Inc (NASDAQ:LAB) trade information

Instantly LAB has showed a green trend with a performance of 0.74% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 22.62% year-to-date, but still up 0.37% over the last five days. On the other hand, Standard BioTools Inc (NASDAQ:LAB) is 14.35% up in the 30-day period. We can see from the shorts that 9.26 million shares have been sold at a short interest cover period of 4.91 day(s).

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 8.72%.

LAB Dividends

Standard BioTools Inc’s next quarterly earnings report is expected to be released around May 07 and May 13.

Standard BioTools Inc (NASDAQ:LAB)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 0.64% of Standard BioTools Inc shares, and 56.02% of them are in the hands of institutional investors. The stock currently has a share float of 56.38%. Standard BioTools Inc stock is held by 121 institutions, with Indaba Capital Management, L.P. being the largest institutional investor. By Dec 30, 2023, it held 2.57% of the shares, which is about 7.45 million shares worth $20.18 million.

Caligan Partners, LP, with 2.43% or 7.04 million shares worth $19.08 million as of Dec 30, 2023, holds the second largest percentage of outstanding shares.

ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jan 30, 2024. The former held 13.42 million shares worth $36.36 million, making up 4.62% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.86 million shares worth around $7.74 million, which represents about 0.98% of the total shares outstanding.